within Pharmacolibrary.Drugs.ATC.R;

model R03AK11
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.2,
    Cl             = 18.333333333333332,
    adminDuration  = 600,
    adminMass      = 0.012,
    adminCount     = 1,
    Vd             = 0.3,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Formoterol and fluticasone is a fixed-dose combination medication consisting of formoterol, a long-acting beta2-adrenergic agonist (LABA), and fluticasone propionate, an inhaled corticosteroid (ICS), used in the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). It is approved in several regions as a combination inhaler for regular use in adults and adolescents.</p><h4>Pharmacokinetics</h4><p>Estimates for healthy adult population after inhalation as published pharmacokinetic studies for the combination under ATC R03AK11 are lacking; values are approximated based on literature of each individual component when given as an inhaled combination.</p><h4>References</h4><ol><li><p>Dissanayake, S, et al., &amp; Dalvi, P (2023). Pharmacokinetic and Pharmacodynamic Comparison of Fluticasone Propionate/Formoterol Fumarate Administered via a Pressurized Metered-Dose Inhaler and a Novel Breath-Actuated Inhaler in Healthy Volunteers. <i>Journal of aerosol medicine and pulmonary drug delivery</i> 36(2) 65–75. DOI:<a href=&quot;https://doi.org/10.1089/jamp.2022.0064&quot;>10.1089/jamp.2022.0064</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36796001/&quot;>https://pubmed.ncbi.nlm.nih.gov/36796001</a></p></li><li><p>McKeage, K (2013). Fluticasone propionate/formoterol fumarate: a review of its use in persistent asthma. <i>Drugs</i> 73(2) 195–206. DOI:<a href=&quot;https://doi.org/10.1007/s40265-013-0016-4&quot;>10.1007/s40265-013-0016-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23397367/&quot;>https://pubmed.ncbi.nlm.nih.gov/23397367</a></p></li><li><p>Usmani, O, et al., &amp; Price, D (2019). An innovative corticosteroid/long-acting β. <i>Expert opinion on drug delivery</i> 16(12) 1367–1380. DOI:<a href=&quot;https://doi.org/10.1080/17425247.2019.1689957&quot;>10.1080/17425247.2019.1689957</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31752560/&quot;>https://pubmed.ncbi.nlm.nih.gov/31752560</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end R03AK11;
